Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington’s disease peripheral blood samples

IntroductionMetabolic changes have been frequently associated with Huntington’s disease (HD). At the same time peripheral blood represents a minimally invasive sampling avenue with little distress to Huntington’s disease patients especially when brain or other tissue samples are difficult to collect.ObjectivesWe investigated the levels of 163 metabolites in HD patient and control serum samples in order to identify disease related changes. Additionally, we integrated the metabolomics data with our previously published next generation sequencing-based gene expression data from the same patients in order to interconnect the metabolomics changes with transcriptional alterations.MethodsThis analysis was performed using targeted metabolomics and flow injection electrospray ionization tandem mass spectrometry in 133 serum samples from 97 Huntington’s disease patients (29 pre-symptomatic and 68 symptomatic) and 36 controls.ResultsBy comparing HD mutation carriers with controls we identified 3 metabolites significantly changed in HD (serine and threonine and one phosphatidylcholine—PC ae C36:0) and an additional 8 phosphatidylcholines (PC aa C38:6, PC aa C36:0, PC ae C38:0, PC aa C38:0, PC ae C38:6, PC ae C42:0, PC aa C36:5 and PC ae C36:0) that exhibited a significant association with disease severity. Using workflow based exploitation of pathway databases and by integrating our metabolomics data with our gene expression data from the same patients we identified 4 deregulated phosphatidylcholine metabolism related genes (ALDH1B1, MBOAT1, MTRR and PLB1) that showed significant association with the changes in metabolite concentrations.ConclusionOur results support the notion that phosphatidylcholine metabolism is deregulated in HD blood and that these metabolite alterations are associated with specific gene expression changes.

[1]  M. Katan,et al.  Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men. , 2005, The American journal of clinical nutrition.

[2]  Xi-jun Wang,et al.  Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma , 2013, Hepatology.

[3]  A. Deckel.  Nitric oxide and nitric oxide synthase in Huntington's disease , 2001, Journal of neuroscience research.

[4]  H. Bading,et al.  Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders , 2010, Nature Reviews Neuroscience.

[5]  J. Kaput,et al.  Neuroscience and Biobehavioral Reviews B Vitamin Polymorphisms and Behavior: Evidence of Associations with Neurodevelopment, Depression, Schizophrenia, Bipolar Disorder and Cognitive Decline , 2022 .

[6]  J. Growdon.  Use of Phosphatidylcholine in Brain Diseases: An Overview , 1987 .

[7]  Alexandra Durr,et al.  Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease Progression , 2007, PloS one.

[8]  J. Goeman,et al.  Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood , 2015, European Journal of Human Genetics.

[9]  Á. Simonyi,et al.  Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. , 2004, Journal of lipid research.

[10]  Masanori Arita,et al.  MS-DIAL: Data Independent MS/MS Deconvolution for Comprehensive Metabolome Analysis , 2015, Nature Methods.

[11]  Stuart Maudsley,et al.  Metabolic and hormonal signatures in pre-manifest and manifest Huntington's disease patients , 2014, Front. Physiol..

[12]  J. Slotte,et al.  Biological functions of sphingomyelins. , 2013, Progress in lipid research.

[13]  J. Marcinkowski,et al.  Skeletal muscle pathology in Huntington's disease , 2014, Front. Physiol..

[14]  X. Arakaki,et al.  Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease[S] , 2013, Journal of Lipid Research.

[15]  Johan T den Dunnen,et al.  Increased sensitivity of next generation sequencing-based expression profiling after globin reduction in human blood RNA , 2012, BMC Genomics.

[16]  Jing Liu,et al.  Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression , 2012, Cell.

[17]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[18]  Fanny Mochel,et al.  Energy deficit in Huntington disease: why it matters. , 2011, The Journal of clinical investigation.

[19]  Chris Frost,et al.  Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data , 2013, The Lancet Neurology.

[20]  A. Durr,et al.  Validation of plasma branched chain amino acids as biomarkers in Huntington disease. , 2011, Archives of neurology.

[21]  J. Olson,et al.  Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease , 2005, The Journal of Neuroscience.

[22]  I. Abeles,et al.  Dietary arginine alters time of symptom onset in Huntington’s disease transgenic mice 1 1 Published on the World Wide Web on 27 July 2000. , 2000, Brain Research.

[23]  G. S. Rosenberg,et al.  The use of cholinergic precursors in neuropsychiatric diseases. , 1982, The American journal of clinical nutrition.

[24]  N. Scrutton,et al.  Mechanism of coenzyme binding to human methionine synthase reductase revealed through the crystal structure of the FNR-like module and isothermal titration calorimetry. , 2007, Biochemistry.

[25]  J. Hardin,et al.  Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington’s disease patients , 2012, Neurological Sciences.

[26]  J. Adamski,et al.  Altered levels of acylcarnitines, phosphatidylcholines, and sphingomyelins in peritoneal fluid from ovarian endometriosis patients , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[27]  Christoph Steinbeck,et al.  The ChEBI reference database and ontology for biologically relevant chemistry: enhancements for 2013 , 2012, Nucleic Acids Res..

[28]  Christian Gieger,et al.  Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting , 2010, PloS one.

[29]  E. Cattaneo,et al.  Emerging roles for cholesterol in Huntington's disease , 2011, Trends in Neurosciences.

[30]  R. Dempsey,et al.  Lipids and lipidomics in brain injury and diseases , 2006, The AAPS Journal.

[31]  Christian Gieger,et al.  Genome-wide association study identifies novel genetic variants contributing to variation in blood metabolite levels , 2015, Nature Communications.

[32]  M. Flint Beal,et al.  PGC-1α, mitochondrial dysfunction, and Huntington's disease. , 2013, Free radical biology & medicine.

[33]  C. A. Toro,et al.  A failure in energy metabolism and antioxidant uptake precede symptoms of Huntington’s disease in mice , 2013, Nature Communications.

[34]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[35]  J. Olson,et al.  Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.

[36]  M. L. Cristina,et al.  Urinary hydroxyproline as a biomarker of effect after exposure to nitrogen dioxide. , 2002, Toxicology letters.

[37]  T. Spector,et al.  Genetic Influences on Metabolite Levels: A Comparison across Metabolomic Platforms , 2016, PloS one.

[38]  Aaron D. Wilson,et al.  Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Susumu Goto,et al.  KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..

[40]  R. Beger,et al.  Metabolomic biomarkers: their role in the critical path. , 2007, Drug discovery today. Technologies.

[41]  Ryan Miller,et al.  WikiPathways: capturing the full diversity of pathway knowledge , 2015, Nucleic Acids Res..

[42]  K. Shannak,et al.  Striatal ganglioside levels in the rat following kainic acid lesions: Comparison with Huntington's disease , 2004, Experimental Brain Research.

[43]  Christian Gieger,et al.  Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum , 2008, PLoS genetics.

[44]  Y. Zilberter,et al.  A unique array of neuroprotective effects of pyruvate in neuropathology , 2015, Front. Neurosci..

[45]  D. Jenden,et al.  Folate nutriture alters choline status of women and men fed low choline diets. , 1999, The Journal of nutrition.

[46]  J. Li,et al.  Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix , 2005, Heredity.

[47]  Whole gene expression profile in blood reveals multiple pathways deregulation in R6/2 mouse model , 2013, Biomarker Research.

[48]  Christian Gieger,et al.  A genome-wide perspective of genetic variation in human metabolism , 2010, Nature Genetics.

[49]  J. Ryu,et al.  Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington’s disease , 2003, Experimental Neurology.

[50]  P. Karp,et al.  Computational prediction of human metabolic pathways from the complete human genome , 2004, Genome Biology.

[51]  J. Cheverud,et al.  A simple correction for multiple comparisons in interval mapping genome scans , 2001, Heredity.

[52]  J. Andrich,et al.  Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD , 2004, Movement disorders : official journal of the Movement Disorder Society.

[53]  G. De Michele,et al.  Growth hormone response to arginine test differentiates between two subgroups of Huntington's disease patients , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[54]  S. Tabrizi,et al.  Disruption of immune cell function by mutant huntingtin in Huntington's disease pathogenesis. , 2016, Current opinion in pharmacology.

[55]  M. Jaworska,et al.  Huntington' disease--imbalance of amino acid levels in plasma of patients and mutation carriers. , 2013, Annals of agricultural and environmental medicine : AAEM.

[56]  Y. Liu,et al.  Sterols and sphingolipids: dynamic duo or partners in crime? , 2010, Progress in lipid research.

[57]  E. Holmes,et al.  Metabonomic Characterization of the 3-Nitropropionic Acid Rat Model of Huntington’s Disease , 2009, Neurochemical Research.

[58]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[59]  R. M. Adibhatla,et al.  Altered lipid metabolism in brain injury and disorders. , 2008, Sub-cellular biochemistry.

[60]  E. Bonilla,et al.  Huntington's disease: studies on brain free amino acids. , 1988, Life sciences.

[61]  David Broadhurst,et al.  Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. , 2006, Brain : a journal of neurology.

[62]  S. Lorenzl,et al.  Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations , 2009, Expert review of neurotherapeutics.

[63]  Christian Gieger,et al.  On the hypothesis-free testing of metabolite ratios in genome-wide and metabolome-wide association studies , 2012, BMC Bioinformatics.

[64]  V. Silani,et al.  Huntington's disease: The current state of research with peripheral tissues , 2009, Experimental Neurology.

[65]  F. Kronenberg,et al.  Influence of hematocrit on the measurement of lipoproteins demonstrated by the example of lipoprotein(a). , 1998, Kidney international.

[66]  J. Olson,et al.  Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. , 2002, Human molecular genetics.

[67]  G. van Ommen,et al.  Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide , 2011, PloS one.

[68]  T. Shea,et al.  Deprivation of folate and B12 increases neurodegeneration beyond that accompanying deprivation of either vitamin alone. , 2009, Journal of Alzheimer's disease : JAD.

[69]  Jerzy Adamski,et al.  Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics , 2011, Metabolomics.

[70]  D. Selkoe,et al.  Cytosolic Phospholipase A2(cPLA2) Immunoreactivity Is Elevated in Alzheimer's Disease Brain , 1996, Neurobiology of Disease.

[71]  Beate Sick,et al.  Dysregulation of Gene Expression in Primary Neuron Models of Huntington's Disease Shows That Polyglutamine-Related Effects on the Striatal Transcriptome May Not Be Dependent on Brain Circuitry , 2008, The Journal of Neuroscience.

[72]  Christian Gieger,et al.  Automated workflow-based exploitation of pathway databases provides new insights into genetic associations of metabolite profiles , 2013, BMC Genomics.

[73]  C. Banchio,et al.  Phosphatidylcholine Biosynthesis during Neuronal Differentiation and Its Role in Cell Fate Determination* , 2010, The Journal of Biological Chemistry.

[74]  K. Hoyt,et al.  Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease , 2007, Neurobiology of Disease.

[75]  L. Stolk,et al.  Homocysteine and DNA methylation: a review of animal and human literature. , 2014, Molecular genetics and metabolism.

[76]  Jane S. Paulsen,et al.  Huntington disease: natural history, biomarkers and prospects for therapeutics , 2014, Nature Reviews Neurology.

[77]  U. Ceglarek,et al.  Validation of the Phenylalanine/Tyrosine Ratio Determined by Tandem Mass Spectrometry: Sensitive Newborn Screening for Phenylketonuria , 2002, Clinical chemistry and laboratory medicine.

[78]  高村 歩美.  Enhanced autophagy and mitochondrial aberrations in murine G[M1]-gangliosidosis , 2008 .

[79]  J. Sutcliffe,et al.  Glycolipid and ganglioside metabolism imbalances in Huntington's disease , 2007, Neurobiology of Disease.

[80]  M. Shattock,et al.  Cardiac Dysautonomia in Huntington's Disease. , 2013, Journal of Huntington's disease.

[81]  David S. Wishart,et al.  MetaboAnalyst 3.0—making metabolomics more meaningful , 2015, Nucleic Acids Res..

[82]  David Eidelberg,et al.  Metabolic network as a progression biomarker of premanifest Huntington's disease. , 2013, The Journal of clinical investigation.

[83]  T. Azuma,et al.  Metabolomics for Biomarker Discovery in Gastroenterological Cancer , 2014, Metabolites.

[84]  Florian Kronenberg,et al.  Differences between Human Plasma and Serum Metabolite Profiles , 2011, PloS one.

[85]  J. Wherrett,et al.  Erythrocyte glycolipids in Huntington's chorea , 1969, Neurology.

[86]  V. Kostic,et al.  Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. , 2008, Archives of neurology.

[87]  D. Nyholt.  A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. , 2004, American journal of human genetics.

[88]  R. Heipertz,et al.  The fatty acid composition of sphingomyelin from adult human cerebral white matter and changes in childhood, senium and unspecific brain damage , 1977, Journal of Neurology.